{
    "clinical_study": {
        "@rank": "77080", 
        "arm_group": {
            "arm_group_label": "Avastin", 
            "arm_group_type": "Other", 
            "description": "Bevacizumab(Avastin) 0.75mg in 0.03 ml"
        }, 
        "brief_summary": {
            "textblock": "Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In\n      retinopathy of prematurity (ROP).\n\n      Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II."
        }, 
        "brief_title": "Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.", 
        "condition_browse": {
            "mesh_term": [
                "Retinal Diseases", 
                "Retinopathy of Prematurity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II.\n\n        Informed written consent by parents or guardian.\n\n        -\n\n        Exclusion Criteria:\n\n        Refusal to give consent Critically ill neonates.\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "42 Weeks", 
            "minimum_age": "32 Weeks"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707745", 
            "org_study_id": "Avastin for threshold ROP."
        }, 
        "intervention": {
            "arm_group_label": "Avastin", 
            "intervention_name": "Intravitreal Bevacizumab", 
            "intervention_type": "Procedure", 
            "other_name": "Intravitreal Avastin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 15, 2012", 
        "location": {
            "contact": {
                "last_name": "Sivakami A Pai, MS, DNB, Phd", 
                "phone": "00971504148256"
            }, 
            "contact_backup": {
                "email": "maDekhain@dha.gov.ae", 
                "last_name": "Moza A Dekhain, MRCOpthal, FRCS", 
                "phone": "009712195000", 
                "phone_ext": "6272"
            }, 
            "facility": {
                "address": {
                    "city": "Dubai", 
                    "country": "United Arab Emirates", 
                    "state": "UAE"
                }, 
                "name": "Dubai Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Sivakami A Pai, MS, DNB, Phd", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Afra M Lootah, MSc, FRCS", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Arab Emirates"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "last_name": "Sivakami A Pai, MS, DNB, Phd", 
            "phone": "00971504148256"
        }, 
        "overall_contact_backup": {
            "email": "maDekhain@dha.gov.ae", 
            "last_name": "M A Dekhain, FRCS, MRCOpth", 
            "phone": "0097142195000", 
            "phone_ext": "6272"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Arab Emirates: Drug Control Department - Medicines and Pharmacy Control - Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Regression Of ROP", 
            "safety_issue": "Yes", 
            "time_frame": "Minimum 6 months follow up after intravitreal Avastin"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707745"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dubai Health Authority", 
            "investigator_full_name": "Sivakami A Pai", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Recurrence of ROP", 
            "safety_issue": "Yes", 
            "time_frame": "minimum 6 months of follow up."
        }, 
        "source": "Dubai Health Authority", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sivakami A Pai", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}